Myth: feeding your baby egg before it’s a year old will make them allergic to eggs. Reality: When Australian allergists switched up their guidelines to recommend introducing egg to gives between 4 and 6 months old, they saw the number of kids who reacted to eggs drop within three years of the change. Learn more […]
The post The Egg Allergy Myth appeared first on Medical News Bulletin.
You never limit eye care to updating your glasses or getting contact lens prescriptions. Never misunderstand long term visual health as seeing clearly at a distance or reading comfortably up close. You get the understanding all wrong, similar to many others. People not only age. It takes the risks of glaucoma, diabetic eye disease, retinal […]
The post Healthy Vision Takes More Than Glasses — Here’s What Aging Eyes Really Need appeared first on Medical News Bulletin.
A health cover decision should not be based only on what feels sufficient today. Medical expenses change with hospital type, city of treatment, family size and healthcare needs. This is why health insurance policy selection in India needs a forward-looking view. For Indian families, the sum insured should be reviewed as responsibilities change. Government health […]
The post How India’s Medical Cost Trajectory Should Inform Your Sum Insured Decision Today appeared first on Medical News Bulletin.
The Alzheimer’s Association International Conference 2026 will meet in London, with breakthrough research planned across workshops, lectures and plenary sessions.
Laura Nisenbaum, PhD, interim chief science officer of the Alzheimer’s Drug Discovery Foundation, will be at the event, which runs from July 12 to July 15. Healio spoke with her about what she’s looking forward to seeing, what trends will have the most impact and the current state of research.
Healio: Overall, what are the biggest trends in Alzheimer’s research? What impact do you expect these trends to have on care?
Nisenbaum: The
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer.
Pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) was approved as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer.
The FDA based its decision on the randomized phase 3 KEYNOTE-B15/EV-304 trial, which showed a 47% improvement in EFS and a 35% improvement in OS with pembrolizumab plus enfortumab
HELSINKI — As technology evolves, there is potential to quantify and automate presbyopia-correcting IOL selection through measures that evaluate a patient’s ability to neuroadapt to multifocal IOLs.
At the European Society of Cataract and Refractive Surgeons winter meeting, Pei-Fen Lin, MBBS, MA (Cantab), PGDip, FEDIP, FRCOphth, delved into the mechanisms of neuroadaptation as a critical factor in IOL selection because “the eye sees only what the mind is prepared to comprehend,” she said, quoting French philosopher Henri Bergson.
Research has found that 50% of patients implanted with
The FDA favorably reviewed plans for a phase 3 trial of urcosimod, which is being investigated for the treatment of neuropathic corneal pain, according to a press release from Okyo Pharma.
The feedback came during a meeting between Okyo Pharma and the FDA, paving the way for a pivotal trial in a disease that currently has no specifically approved treatments.
“Neuropathic corneal pain remains one of the most challenging and underserved conditions in eye care, with patients often living with persistent pain,” Robert J. Dempsey, CEO of Okyo Pharma, told Healio.
The trial, called
A 10-year study showed that replacing standard hospital surfaces with copper materials cut health care-associated infections by roughly half.
The study, published in the American Journal of Infection Control, tracked health care-associated infection (HAI) rates before and after the installation of 16% to 20% copper oxide on high-touch surfaces at the Central Texas Veterans Health Care System.
The results were no surprise to Chetan Jinadatha, MD, MPH, FIDSA, the study’s corresponding author and chief of infectious diseases at Central Texas Veterans Health Care.
“Copper has antibacterial and
SEATTLE — Use of non-tobacco nicotine such as vapes, nicotine pouches and e-cigarettes was associated with increased complications at 90 days and re-ruptures at 2 years after Achilles tendon repair, according to results presented here.
“Nicotine is a vasoconstrictor. There has been a lot of basic science [research] done that shows this independently affects tissue perfusion, promotes immune dysfunction and increases oxidative stress,” Jalen Warren, DO, orthopedic surgery resident at Case Western Reserve University, said in his presentation at the American Orthopaedic Society
Nearly 1 in 3 academic dermatologists left academia during a 7-year period, with career stage, research productivity and NIH funding among the factors that affected their long-term retention, according to new research.
Retention of academic dermatologists is vitally important to the field, with these faculty members responsible for training and mentoring future physicians, leading research and caring for patients with complex conditions, according to Allen F. Shih, MD, MBA, medical director of dermatology at Beth Israel Deaconess Medical Center. Academic dermatology turnover can have lasting